If peripherally located CB1Rs do contribute to metabolic regulation, then restricting the penetrance of CB1R antagonists to the brain may improve their therapeutic index by reducing/eliminating the risk for neuropsychiatric side effects that were observed in obese subjects [34], [35] and in humans with PWS [12] treated with rimonabant. Here, CNR1 is linked to Prader-Willi syndrome.